The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Capecitabine (Cape) versus 5-fluorouracil (5-FU)–based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial.
R. Hofheinz
Consultant or Advisory Role - Amgen; Merck KGaA; Roche
Honoraria - Amgen; Merck KGaA; Roche
Research Funding - Roche
F. K. Wenz
No relevant relationships to disclose
S. Post
No relevant relationships to disclose
A. Matzdorff
No relevant relationships to disclose
S. Laechelt
No relevant relationships to disclose
J. T. Hartmann
No relevant relationships to disclose
L. Müller
No relevant relationships to disclose
H. Link
Honoraria - Roche; Sanofi
Research Funding - Roche; Sanofi
M. H. Moehler
No relevant relationships to disclose
E. Kettner
No relevant relationships to disclose
E. Fritz
No relevant relationships to disclose
U. Hieber
No relevant relationships to disclose
H. W. Lindemann
No relevant relationships to disclose
M. Grunewald
No relevant relationships to disclose
S. Kremers
No relevant relationships to disclose
C. Constantin
No relevant relationships to disclose
M. Hipp
Consultant or Advisory Role - Merck KGaA
D. Gencer
No relevant relationships to disclose
I. Burkholder
No relevant relationships to disclose
A. Hochhaus
Research Funding - Roche